A hospital based case-control study was conducted to test the hypothesis of a lower lung cancer risk in G6PD-deficient subjects. Cases were 156 male patients with lung cancer, admitted to « Binaghi » Hospital, Local Health Unit (USL) 20, Cagliari (Italy), between January 1984 and November 1986. Controls were 235 male patients, admitted to the same hospital In the same time period, for diseases other than cancer (all types) and hemolytic anemia. No decrease of the lung cancer risk was found in G6PD-deficient subjects. This result, in line with recent reports in the literature, suggests that the genetic condition of G6PD deficiency does not provide significant protection against the development of lung cancer in humans.
Get full access to this article
View all access options for this article.
References
1.
BeaconsfieldP., RainsburyR., KaltonG.: Glucose-6-phos-phate dehydrogenase deficiency and the incidence of cancer.Oncologia, 19: 11–16, 1965.
2.
CoccoP.L.: Does G6PD deficiency protect against cancer? A critical review.J. Epidemiol. Community Health, 41: 89–93, 1987.
3.
CoccoP.L., ColluR., DessìS., PaniP.: Frequency of G6PD deficiency and age: a correlation study.In: Abstracts of the 3rd Sardinian Meeting: Agents and Processes in Chemical Carcinogenesis, p. 104. ColumbanoA. ed., Cagliari, Italy, 1985.
4.
CoccoP.L., DessìS., AvataneoG., PicchiriG.F., HeinemannH.: Glucose-6-phosphate dehydrogenase deficiency and cancer in a Sardinian male population: a case-control study.Carcinogenesis, 10: 813–816, 1989.
5.
CoccoP.L., MancaP., DessìS.: Preliminary results of a geographic correlation study on G6PD deficiency and cancer.Toxicol. Pathol., 15: 106–108, 1987.
6.
DessìS., BatettaB., CherchiR., OnnisR., PisanoM., PaniP.: Hexose monophosphate shunt enzymes in lung tumors from normal and glucose-6-phosphate dehydrogenase deficient subjects.Oncology, 45: 287–291, 1986.
7.
DessìS., BatettaB., LaconiE., EnnasC., PaniP.: Hepatic cholesterol in lead nitrate induced liver proliferation.Chem.-Biol. Interact., 48: 271–279, 1984.
8.
DessìS., ChiodinoC., BatettaB., LaconiE., EnnasC., PaniP.: Hexose monophosphate shunt and cholesterol synthesis in the diabetic and fasting states.Exp. Mol. Pathol., 43: 177–186, 1985.
9.
FeoF., PirisiL., PascaleR.: Modulatory effect of glucose-6-phosphate dehydrogenase deficiency on benzo(a)-pyrene toxicity and transforming activity for in vitro-cultured human skin fibroblasts.Cancer Res., 44: 3419–3425, 1984.
10.
FerrarisA.M., BrocciaG., MeloniT., ForteleoniG., GaetaniG.F.: Glucose-6-phosphate dehydrogenase deficiency and incidence of hematologic malignancies.Am. J. Hum. Genet., 42: 516–520, 1988.
11.
Ledda-ColumbanoG.M., ColumbanoA., DessìS., ConiP., ChiodinoC., PaniP.: Enhancement of cholesterol synthesis and pentose phosphate pathway activity in proliferating hepatocyte nodules.Carcinogenesis, 6: 1371–1373, 1985.
12.
MantelN., HaenszelW.: Statistical aspects of the analysis of data from retrospective studies.J. Natl. Cancer Inst., 32: 719–748, 1959.
13.
MiettinenO.S.: Components of the crude risk ratio.Am. J. Epidemiol., 96: 168–172, 1972.
14.
MiettinenO.S.: Estimability and estimation in case-referent studies.Am. J. Epidemiol., 103: 226–235, 1976.
15.
NaikS.N., AndersonD.E.: The association between glucose-6-phosphate dehydrogenase deficiency and cancer in American Negroes.Oncology, 25: 356–364, 1971.
16.
PaniP., DessìS., RaoK.N., BatettaB., LaconiE.: Changes in serum and hepatic cholesterol in lead induced liver hyperplasia.Toxicol. Pathol., 12: 162–167, 1984.
17.
PanizonF.: Studio dell'attività enzimatica della mucosa digiunale in soggetti con G6PD-penia eritrocitaria.Studi Sassaresi, 39: 710–718, 1961.
18.
PannacciulliI., TizianelloA., SalvidioE.: L'attività della G6PD e 6PGD dei leucociti, delle piastrine, delle cellule midollari, spleniche, epatiche e di tessuto gastrico in soggetti con eritroenzimopenia familiare.Boll. Soc. Ital. Biol. Sper., 42: 1552–1555, 1966.
19.
PashkoL.L., HardG.C., RovitoR.J., WilliamsJ.R., SobelE.L., SchwartzA.G.: Inhibition of 7, 12-dimethylbenz(a)-anthracene-induced skin papillomas and carcinomas by dehy-droepiandrosterone and 3-beta-methylandrost-5-en-17-one in mice.Cancer Res., 45: 164–166, 1985.
20.
RamotB., SzeinbergA., AdamA., ShebaC., GafniD.: A study of subjects with erythrocyte glucose-6-phosphate dehydrogenase deficiency: investigation on platelets enzymes.J. Clin. Invest., 30: 1659–1661, 1959.
21.
RamotB., SzeinbergA., AdamA., ShebaC., GafniD.: A study of subjects with erythrocyte glucose-6-phosphate dehydrogenase deficiency: investigation on leucocytic enzymes.J. Clin. Invest., 30: 2234–2237, 1959.
22.
RaoK.N., KottapallyS., ShinozukaH.: Acinar cell carcinoma of rat pancreas: mechanism of deregulation of cholesterol metabolism.Toxicol. Pathol., 12: 62–68, 1984.
SchwartzA.G., NyceJ.W., TannenR.H.: Inhibition of tumorigenesis and autoimmune development in mice by dehydroepiandrosterone.In: Vv. Aa.: Altered Endocrine Status during Aging, pp. 177–184, Liss Publ., New York, 1984.
25.
SchwartzA.G., PashkoL.L., HendersonE.E.: Dehydroepiandrosterone: an anti-obesity and anticarcinogenic agent.Comm. Res. Breast Dis., 3: 130–136, 1983.
26.
SchwartzA.G., PerantoniA.: Protective effect of dehydroepiandrosterone against aflatoxin B1- and 7,12-dimethyl-benz(a)anthracene-induced cytotoxicity and transformation in cultured cells.Cancer Res., 35: 2452–2457, 1975.
27.
SchwartzA.G., TannenR.H.: Inhibition of 7,12-dymethyl-benz(a) anthracene- and urethane-induced lung tumor formation in A/J mice by long term treatment with dehydroepiandrosterone.Carcinogenesis, 2: 1335–1337, 1981.
28.
SiniscalcoM., BerniniL., LatteB., MotulskyA.G.: Favism and thalassaemia in Sardinia and their relationship to malaria.Nature, 190: 1179–1180, 1961.
29.
SulisE., SpanoG.: Osservazioni preliminari sull'incidenza neoplastica e sul comportamento enzimatico e proliferativo del tessuto tumorale negli individui carenti di Glucosio-6-Fosfato Deidrogenasi (G6PD).Boll. Soc. Ital. Biol. Sper., 44: 1246–1249, 1968.
